By creator to www.ptcommunity.com
MANSFIELD, Mass., Might 29, 2020 /PRNewswire/ — Transplant Genomics Inc. (TGI), the chief in bringing personalised diagnostics to transplant sufferers worldwide, declares that TGI Scientific Advisor, Dr. John Friedewald of Northwestern College will obtain a high honor on the American Transplant Congress (ATC2020). On June 1, Dr. Friedewald will obtain The American Journal of Transplantation (AJT) 2020 Excellent Article Award in Translational Science for his groundbreaking scientific publication. “Improvement and medical validity of a novel blood-based molecular biomarker for sub-clinical acute rejection following kidney transplant” was printed within the January 2019 version of AJT.
The paper, by Dr. Friedewald and his colleagues, studies on the event and validation of blood-based biomarkers to rule out “silent” subclinical acute rejection (subAR) in secure kidney transplant sufferers. The NIH-funded, multi-center Scientific Trials in Organ Transplantation (CTOT08) examine, which knowledgeable the paper, definitively establishes that secure kidney transplant sufferers with biopsy-proven subAR have worse outcomes than those that don’t have subAR. The examine additionally reveals that non-invasive blood assessments are simply as efficient at ruling out subAR as invasive surveillance biopsies and are a viable, less-risky different to serially monitor secure kidney sufferers.
Out of the 307 secure sufferers studied over 24 months in CTOT08, ~25% have been proven to have subAR, a situation additionally proven to negatively impression graft outcomes. Previous to this examine, the one method to monitor sufferers for subAR was to carry out serial invasive surveillance biopsies. Contemplating ~75% of sufferers have been discovered to be damaging for subAR, Friedewald says these biopsies can expose sufferers to pointless danger.
The findings are significantly related at the moment, as medical doctors search for new methods to guard transplant sufferers from COVID-19. As an alternative of bringing secure sufferers into the hospital for a biopsy – the place danger to COVID-19 publicity could be excessive and assets could be scarce – this non-invasive check could be finished repeatedly by accumulating blood samples at house utilizing a cell phlebotomist.
TGI holds the U.S. patent on the usage of blood gene expression profiling by numerous technical approaches to rule out subAR. The CLIA-certified laboratory started providing the primary business check utilizing this method, TruGraf®, in 2019. It was developed and validated as the primary and solely blood check to non-invasively rule out silent rejection in secure kidney transplant recipients lined by The Facilities for Medicare and Medicaid Providers (CMS). TruGraf® is indicated to be used in renal transplant sufferers who’re not less than 18 years outdated and not less than 90 days post-transplant with secure serum creatinine values.
Blood samples for TruGraf® testing could be collected by way of TGI’s newly launched Labs@Residence program. For data on ordering assessments and arranging distant pattern assortment, physicians could contact TGI at 1-844-TruGraf. Ordering and normal data can be out there on our web sites at www.trugraf.com.
Sloane Heller Communications
About Transplant Genomics, Inc.
Transplant Genomics, Inc. (“TGI”) is a molecular diagnostics firm bringing personalised diagnostics to transplant sufferers worldwide, with an preliminary give attention to kidney transplant recipients. Working with the transplant neighborhood, TGI is commercializing a set of assessments enabling analysis and prediction of transplant recipient immune standing. Take a look at outcomes will assist clinicians with data to optimize immune-suppressive remedy, improve affected person care and enhance graft survival. Take a look at companies are supplied by way of TGI’s CLIA laboratory in Fremont, CA.
Eurofins – a worldwide chief in bio-analysis
Eurofins Scientific by way of its subsidiaries (hereinafter typically “Eurofins” or “the Group”) believes it’s a scientific chief in meals, setting, pharmaceutical and cosmetics merchandise testing and in agroscience CRO companies. Additionally it is one of many international impartial market leaders in sure testing and laboratory companies for genomics, discovery pharmacology, forensics, CDMO, superior materials sciences and for supporting medical research. As well as, Eurofins is among the main international rising gamers in specialty medical diagnostic testing. With about 45,000 employees in additional than 800 laboratories throughout 47 nations, Eurofins provides a portfolio of over 200,000 analytical strategies for evaluating the protection, id, composition, authenticity, origin and purity of organic substances and merchandise, in addition to for progressive medical diagnostic. The Group goal is to supply its clients with high-quality companies, correct outcomes on time and knowledgeable recommendation by its extremely certified employees.
Eurofins is dedicated to pursuing its dynamic development technique by increasing each its expertise portfolio and its geographic attain. By R&D and acquisitions, the Group attracts on the newest developments within the subject of biotechnology and analytical chemistry to supply its purchasers distinctive analytical options and essentially the most complete vary of testing strategies.
As some of the progressive and high quality oriented worldwide gamers in its business, Eurofins is ideally positioned to assist its purchasers’ more and more stringent high quality and security requirements and the increasing calls for of regulatory authorities around the globe.
The shares of Eurofins Scientific are listed on the Euronext Paris Inventory Change (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
View unique content material to obtain multimedia:http://www.prnewswire.com/news-releases/the-american-journal-of-transplantation-honors-transplant-genomics-advisor-with-2020-outstanding-article-award-301067956.html
SOURCE Transplant Genomics, Inc.
— to www.ptcommunity.com